


2-23-04

Express Mail Label No.: EV 392154180 US  
Date of Deposit: February 20, 2004

Attorney Docket No.: 18427-001 CON2



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

APPLICANTS: Sarvetnick, *et al.*  
SERIAL 10/672,685 EXAMINER: Not yet assigned  
NUMBER:  
FILING DATE: September 26, 2003 ART UNIT: 1641  
FOR: PANCREATIC PROGENITOR CELLS AND METHODS FOR  
ISOLATING THE SAME

**Mail Stop IDS**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**TRANSMITTAL LETTER**

Transmitted herewith for filing in the present application are the following documents:

1. Information Disclosure Statement (1 page), in duplicate;
2. Modified Form 1449/PTO (2 pages), in duplicate; and
3. Return Postcard.


If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (617) 542-6000, Boston, Massachusetts.

The Commissioner is authorized to charge any fees that may be due, or to credit any overpayment, to the undersigned's account, Deposit Account No. 50-0311, Ref. No. 18427-001 CON2. A duplicate copy of this transmittal letter is enclosed herewith.

Respectfully submitted,

*for Janine M. Susan, Reg. No. 46,119*  
Ivor R. Elrifi, Reg. No. 39,529  
Attorney for Applicants  
MINTZ, LEVIN, COHN, FERRIS,  
GLOVSKY and POPEO, P.C.  
One Financial Center  
Boston, Massachusetts 02111  
Tel: (617) 542-6000  
Fax: (617) 542-2241  
Customer No. 30623

Dated: February 20, 2004



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Sarvetnick, *et al.*

SERIAL  
NUMBER: 10/672,685

EXAMINER: Not yet assigned

FILING DATE: September 26, 2003

ART UNIT: 1641

FOR: PANCREATIC PROGENITOR CELLS AND METHODS FOR ISOLATING  
THE SAME

**Mail Stop IDS**

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT**

Applicants hereby make of record the documents listed on the attached modified Form PTO-1449 (submitted in duplicate) in the above-identified application. This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits in the above-identified case. Accordingly, no fee or certification is believed required. Copies of the references are not provided as they were previously cited and/or submitted to the USPTO in prior applications, Serial No. 09/826,779, filed April 5, 2001, and Serial No. 09/212,531, filed December 16, 1989, and relied upon for an earlier filing date under 35 U.S.C. § 120 (continuation, continuation-in-part, and divisional applications). Please charge any fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311 Reference No. 18427-001 CON2.

Respectfully submitted,

*for* Janine M. Susan, Reg. No. 46,119  
Ivor R. Elrifi, Reg. No. 39,529  
Attorney for Applicants  
MINTZ, LEVIN, COHN, FERRIS,  
GLOVSKY and POPEO, P.C.  
One Financial Center  
Boston, Massachusetts 02111  
Tel: (617) 542-6000  
Fax: (617) 542-2241  
Customer No. 30623

Dated: February 20, 2004



Please type a plus sign (+) in this box



PTO/SB (12-97)  
Approved for use through 9/30/00. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Modified Form 1449/PTO				Application Number		10/672,685	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				Filing Date		September 26, 2003	
				First Named Inventor		Sarvetnick	
				Group Art Unit		1641	
				Examiner Name		Not Yet Assigned	
				Attorney Docket Number		18427-001 CON2	
<b>U.S. PATENT DOCUMENTS</b>							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
	A1	**5,849,989	12/15/98	Edlund	800	2	
	A2	**5,858,973	01/12/99	Habener, et al.	514	12	
	A3	**6,326,201 B1	12/04/01	Fung, et al.	435	377	
<b>FOREIGN PATENT DOCUMENTS</b>							
Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No		
	B1	*WO 98/26044	The Regents of The University of California	06/18/98			
	B2	*WO 96/11949	Amgen, Inc.	04/25/96			
	B3	*WO 96/40872	Ontogeny, Inc.	12/19/96			
	B4	*WO 98/16243	Amgen, Inc.	04/23/98			
	B5	*EP 0 363 125	Hana Biologics, Inc.	04/11/90			
<b>OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS</b>							
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.					
	C1	*Amush <i>et al.</i> , "Growth factors in the regenerating pancreas of gamma-interferon transgenic mice," <i>Lab. Invest.</i> 74: 985-990 (1996).					
	C2	*Gu <i>et al.</i> , "Epithelial cell proliferation and islet neogenesis in IFN-g transgenic mice," <i>Development</i> , 118: 33-46 (1993).					
	C3	*Guo <i>et al.</i> , "Targeting expression of keratinocyte growth factor to keratinocytes elicits striking changes in epithelial differentiation in transgenic mice," <i>EMBO J.</i> , 12: 973-986 (1993).					
	C4	*Housley <i>et al.</i> , "Keratinocyte growth factor induces proliferation of hepatocytes and, epithelial cells throughout the rat gastrointestinal tract," <i>J. Clin. Invest.</i> , 94: 1764-1777 (1994).					
	C5	*Nguyen, <i>et al.</i> , "Expression of keratinocyte growth factor in embryonic liver of transgenic mice causes changes in epithelial growth and differentiation resulting in polycystic kidneys and other organ malformations," <i>Oncogene</i> , 12: 2109-2119 (1996).					
	C6	*Sarvetnick <i>et al.</i> , "Insulin-dependent diabetes mellitus induced in transgenic mice by ectopic expression of class III MHC and interferon-gamma," <i>Cell</i> , 52: 773-782 (1988).					
	C7	*Yi <i>et al.</i> , "Keratinocyte growth factor induces pancreatic ductal epithelial proliferation," <i>Am. J. Pathol.</i> , 145: 80-85 (1994).					
	C8	*Peshavaria & Stein, <i>Pancreatic Growth and Regeneration</i> , Chapter 4, Sarvetnick, ed. (Karger Lander Systems, 1997).					
	C9	*Jones & Sarvetnick, 29, <i>Horm. Metab. Res.</i> , 308-310 (1997).					
	C10	*Krakowski <i>et al.</i> , 162, <i>J. Endocrinology</i> , 167-175 (1999).					
	C11	*Kritzik <i>et al.</i> , 163, <i>J. Endocrinology</i> , 523-530 (1999).					
	C12	*Krakowski <i>et al.</i> , 154(3), <i>Am. J. Pathology</i> , 683-691 (March 1999).					
	C13	*Ebert, <i>et al.</i> , <i>Mol. Endocrinol.</i> , 2:277-283 (1988).					
	C14	*Wall, <i>et al.</i> , <i>J. Dairy Sci.</i> , 80(9):2213-2224 (1997).					
	C15	*Tasuda, <i>et al.</i> , <i>J. Biol. Chem.</i> , 273(51):34413-34421 (1998).					
	C16	*Hammer, <i>et al.</i> , <i>J. Anim. Sci.</i> , 63:269-278 (1986).					
	C17	*Itier, <i>et al.</i> , <i>Differentiation</i> , 60:309-316 (1996).					

C18	*Mullins, et al., <i>J. Clin. Invest.</i> , 97(7):1557-1560 (1996).
C13	**O'Reilly, et al., <i>Diabetes</i> , 46:599-606 (1997).
C14	**Fernandes, et al., <i>Endocrinol.</i> , 138:1750-1762 (1997).

\* copies of these references are not provided as they were previously cited by or submitted to the U.S. Patent Office in a prior application, **Serial No. 09/212,531, filed December 16, 1998**, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

\*\* copies of these references are not provided as they were previously cited by or submitted to the U.S. Patent Office in a prior application, **Serial No. 09/826,779, filed April 5, 2001**, which is a Continuing Application of **Serial No. 09/212,531, filed December 16, 1998**, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.

TRA 1887751v1